Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients

Ralph H. Hruban, Patrick D J Sturm, Robbert J C Slebos, Robb E. Wilentz, Alex R. Musler, Charles J. Yeo, Taylor A. Sohn, Marie Louise F Van Velthuysen, G. Johan A Offerhaus

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

It can be difficult to distinguish benign bile duct proliferations (BDPs) from well-differentiated metastatic peripancreatic adenocarcinomas on histological grounds alone. Most peripancreatic carcinomas harbor activating point mutations in codon 12 of the K-ras oncogene, suggesting that K-ras mutational status may provide a molecular basis for distinguishing BDPs from liver metastases. The ability of tests for mutations in codon 12 of K-ras to make this distinction was examined in a two-part study. In the first part we determined the K-ras mutational status of 56 liver lesions and 48 primary peripancreatic adenocarcinomas obtained from 48 patients. In the second part of this study an additional 45 liver lesions were studied. In the first 48 patients, activating point mutations in codon 12 of K-ras were detected in 28 (61%) of the 46 primary carcinomas, in 8 (100%) of 8 liver metastases, in 2 (6.5%) of 31 BDPs, and in none (0%) of 14 liver granulomas. Three BDPs and two primary carcinomas did not amplify. To further estimate the prevalence of K-ras mutations in BDPs we analyzed an additional series of 45 mostly incidental BDPs for K-ras mutations. Three (6.7%) of these 45 harbored K-ras mutations. These results suggest that K-ras mutations may be useful in distinguishing BDPs from metastases in the liver; however, there is some overlap in the mutational spectra of BDPs and pancreatic carcinomas.

Original languageEnglish (US)
Pages (from-to)943-949
Number of pages7
JournalAmerican Journal of Pathology
Volume151
Issue number4
StatePublished - Oct 1997
Externally publishedYes

Fingerprint

Bile Ducts
Codon
Neoplasm Metastasis
Mutation
Liver
Carcinoma
Point Mutation
Adenocarcinoma
ras Genes
Granuloma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Hruban, R. H., Sturm, P. D. J., Slebos, R. J. C., Wilentz, R. E., Musler, A. R., Yeo, C. J., ... Offerhaus, G. J. A. (1997). Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients. American Journal of Pathology, 151(4), 943-949.

Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients. / Hruban, Ralph H.; Sturm, Patrick D J; Slebos, Robbert J C; Wilentz, Robb E.; Musler, Alex R.; Yeo, Charles J.; Sohn, Taylor A.; Van Velthuysen, Marie Louise F; Offerhaus, G. Johan A.

In: American Journal of Pathology, Vol. 151, No. 4, 10.1997, p. 943-949.

Research output: Contribution to journalArticle

Hruban, RH, Sturm, PDJ, Slebos, RJC, Wilentz, RE, Musler, AR, Yeo, CJ, Sohn, TA, Van Velthuysen, MLF & Offerhaus, GJA 1997, 'Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients', American Journal of Pathology, vol. 151, no. 4, pp. 943-949.
Hruban, Ralph H. ; Sturm, Patrick D J ; Slebos, Robbert J C ; Wilentz, Robb E. ; Musler, Alex R. ; Yeo, Charles J. ; Sohn, Taylor A. ; Van Velthuysen, Marie Louise F ; Offerhaus, G. Johan A. / Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients. In: American Journal of Pathology. 1997 ; Vol. 151, No. 4. pp. 943-949.
@article{2a4a4b4249be4cf1a3cc096fb26e4e66,
title = "Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients",
abstract = "It can be difficult to distinguish benign bile duct proliferations (BDPs) from well-differentiated metastatic peripancreatic adenocarcinomas on histological grounds alone. Most peripancreatic carcinomas harbor activating point mutations in codon 12 of the K-ras oncogene, suggesting that K-ras mutational status may provide a molecular basis for distinguishing BDPs from liver metastases. The ability of tests for mutations in codon 12 of K-ras to make this distinction was examined in a two-part study. In the first part we determined the K-ras mutational status of 56 liver lesions and 48 primary peripancreatic adenocarcinomas obtained from 48 patients. In the second part of this study an additional 45 liver lesions were studied. In the first 48 patients, activating point mutations in codon 12 of K-ras were detected in 28 (61{\%}) of the 46 primary carcinomas, in 8 (100{\%}) of 8 liver metastases, in 2 (6.5{\%}) of 31 BDPs, and in none (0{\%}) of 14 liver granulomas. Three BDPs and two primary carcinomas did not amplify. To further estimate the prevalence of K-ras mutations in BDPs we analyzed an additional series of 45 mostly incidental BDPs for K-ras mutations. Three (6.7{\%}) of these 45 harbored K-ras mutations. These results suggest that K-ras mutations may be useful in distinguishing BDPs from metastases in the liver; however, there is some overlap in the mutational spectra of BDPs and pancreatic carcinomas.",
author = "Hruban, {Ralph H.} and Sturm, {Patrick D J} and Slebos, {Robbert J C} and Wilentz, {Robb E.} and Musler, {Alex R.} and Yeo, {Charles J.} and Sohn, {Taylor A.} and {Van Velthuysen}, {Marie Louise F} and Offerhaus, {G. Johan A}",
year = "1997",
month = "10",
language = "English (US)",
volume = "151",
pages = "943--949",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients

AU - Hruban, Ralph H.

AU - Sturm, Patrick D J

AU - Slebos, Robbert J C

AU - Wilentz, Robb E.

AU - Musler, Alex R.

AU - Yeo, Charles J.

AU - Sohn, Taylor A.

AU - Van Velthuysen, Marie Louise F

AU - Offerhaus, G. Johan A

PY - 1997/10

Y1 - 1997/10

N2 - It can be difficult to distinguish benign bile duct proliferations (BDPs) from well-differentiated metastatic peripancreatic adenocarcinomas on histological grounds alone. Most peripancreatic carcinomas harbor activating point mutations in codon 12 of the K-ras oncogene, suggesting that K-ras mutational status may provide a molecular basis for distinguishing BDPs from liver metastases. The ability of tests for mutations in codon 12 of K-ras to make this distinction was examined in a two-part study. In the first part we determined the K-ras mutational status of 56 liver lesions and 48 primary peripancreatic adenocarcinomas obtained from 48 patients. In the second part of this study an additional 45 liver lesions were studied. In the first 48 patients, activating point mutations in codon 12 of K-ras were detected in 28 (61%) of the 46 primary carcinomas, in 8 (100%) of 8 liver metastases, in 2 (6.5%) of 31 BDPs, and in none (0%) of 14 liver granulomas. Three BDPs and two primary carcinomas did not amplify. To further estimate the prevalence of K-ras mutations in BDPs we analyzed an additional series of 45 mostly incidental BDPs for K-ras mutations. Three (6.7%) of these 45 harbored K-ras mutations. These results suggest that K-ras mutations may be useful in distinguishing BDPs from metastases in the liver; however, there is some overlap in the mutational spectra of BDPs and pancreatic carcinomas.

AB - It can be difficult to distinguish benign bile duct proliferations (BDPs) from well-differentiated metastatic peripancreatic adenocarcinomas on histological grounds alone. Most peripancreatic carcinomas harbor activating point mutations in codon 12 of the K-ras oncogene, suggesting that K-ras mutational status may provide a molecular basis for distinguishing BDPs from liver metastases. The ability of tests for mutations in codon 12 of K-ras to make this distinction was examined in a two-part study. In the first part we determined the K-ras mutational status of 56 liver lesions and 48 primary peripancreatic adenocarcinomas obtained from 48 patients. In the second part of this study an additional 45 liver lesions were studied. In the first 48 patients, activating point mutations in codon 12 of K-ras were detected in 28 (61%) of the 46 primary carcinomas, in 8 (100%) of 8 liver metastases, in 2 (6.5%) of 31 BDPs, and in none (0%) of 14 liver granulomas. Three BDPs and two primary carcinomas did not amplify. To further estimate the prevalence of K-ras mutations in BDPs we analyzed an additional series of 45 mostly incidental BDPs for K-ras mutations. Three (6.7%) of these 45 harbored K-ras mutations. These results suggest that K-ras mutations may be useful in distinguishing BDPs from metastases in the liver; however, there is some overlap in the mutational spectra of BDPs and pancreatic carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0030846221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030846221&partnerID=8YFLogxK

M3 - Article

C2 - 9327727

AN - SCOPUS:0030846221

VL - 151

SP - 943

EP - 949

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 4

ER -